Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
TERMINATED
NCT07065617
PHASE1

A Study to Test How BI 1819479 is Taken up and Processed by the Body

Sponsor: Boehringer Ingelheim

View on ClinicalTrials.gov

Summary

This trial is intended to investigate the mass balance, metabolism, and basic pharmacokinetics of BI 1819479 (C-14) (Part A) and to investigate the absolute bioavailability of BI 1819479 (Part B) in healthy male volunteers.

Official title: A Phase I, Open-label, Two-part Trial to Investigate the Mass Balance, Metabolism, and Basic Pharmacokinetics of BI 1819479 (C-14) Administered as an Oral Solution (Part A) and to Investigate the Absolute Bioavailability of BI 1819479 Administered as a Film-coated Tablet Together With an Intravenous Microtracer Dose of [14 C]BI 1819479 (Part B) in Healthy Male Volunteers

Key Details

Gender

MALE

Age Range

18 Years - 55 Years

Study Type

INTERVENTIONAL

Enrollment

7

Start Date

2025-08-04

Completion Date

2025-11-04

Last Updated

2026-08-21

Healthy Volunteers

Yes

Conditions

Interventions

DRUG

[14C]BI 1819479

\[14C\]BI 1819479

DRUG

BI 1819479

BI 1819479

DRUG

BI 1819479 (C-14)

BI 1819479 mixed with \[14C\]BI 1819479

Locations (1)

Quotient Sciences

Nottingham, United Kingdom